Frame 1

Breast Cancer

Cancer Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice

Cancer Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice Question: Are cancer patients receiving appropriate nutritional screening, assessment, and interventions? SUMMARY ANSWER: Cancer Nutrition plays a crucial role for patients with cancer; however, nutritional problems are often under-prioritised, underdiagnosed, and undertreated, thereby affecting treatment outcomes and quality of life WHAT […]

Cancer Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice Read More »

Good Nutrition : The Fifth Pillar Of Cancer Treatment Good Nutrition

Good Nutrition : The Fifth Pillar Of Cancer Treatment Good Nutrition Cancer happens due to the uncontrolled growth of the cells that are the basic building blocks of the body. Having cancer is often an ugly experience at the time of diagnosis followed by a lot of pain, suffering, and heartbreak at the end. Despite

Good Nutrition : The Fifth Pillar Of Cancer Treatment Good Nutrition Read More »

Real world Evidence with Palbociclib in HR+/HER2- MBC in Indian population

Real world Evidence with Palbociclib in HR+/HER2- MBC in Indian population The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination, however, real world evidence in the Indian patients

Real world Evidence with Palbociclib in HR+/HER2- MBC in Indian population Read More »

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer CDK-4/6 inhibitors for the treatment of HR+/HER2 The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination. Hormone

CDK-4/6 inhibitors for the treatment of HR+/HER2 – advanced/metastatic breast cancer Read More »

Scroll to Top